Dassault Systèmes Invests in Click Therapeutics to Advance Digital Therapeutics

What You Should Know: 

– Dassault Systèmes has announced a strategic investment in Click Therapeutics, a pioneering company in prescription digital therapeutics (PDTs) and software-enhanced (SE) drug therapies. This investment signifies Dassault Systèmes’ commitment to transforming the patient experience within the life sciences and healthcare sectors through comprehensive, end-to-end technology solutions.

The investment builds upon the existing collaboration between Dassault Systèmes’ MEDIDATA brand and Click Therapeutics, aiming to enhance patient engagement throughout the entire healthcare journey, from post-trial phases to commercialization. By strengthening this relationship, the companies seek to create a unified offering that sets a new standard for the design and execution of digital and pharmaceutical clinical trials.

This collaboration will facilitate the development and approval of PDTs and SE products, enable expanded labels for existing therapeutics, and establish a novel pipeline for generating long-term, real-world evidence. The combined expertise of Dassault Systèmes and Click Therapeutics will provide unparalleled support for making these innovative therapies accessible to patients.

MEDIDATA, a leader in virtualizing clinical research, has established a robust foundation for creating a seamless patient experience through integrated technology solutions. With over 8,000 active studies conducted annually, MEDIDATA, in partnership with Click Therapeutics, will extend its commitment to patients beyond clinical trials into real-world care. This extension will foster improved coordination and outcomes among patients, physicians, caregivers, and life science manufacturers.

Click Therapeutics will benefit from access to Dassault Systèmes’ global presence and expertise, while both companies will leverage their combined capabilities to accelerate the development and deployment of PDTs and SE products. The collaboration aims to improve patient outcomes by integrating digital therapeutics into the broader healthcare ecosystem.

“Digital therapeutics are beginning to transform the way customers think about their future clinical development programs and are providing demonstrable therapeutic benefits over drugs alone in many cases,” said Anthony Costello, CEO, Medidata. “Today’s investment in Click Therapeutics reflects our commitment to this exciting technology, and our partnership with them will enable our customers to take the fastest, most reliable path to bringing digital therapeutics to patients, helping to build a direct connection to patients over a life-long healthcare journey.”